New Appointment: Acadia Pharmaceuticals has appointed Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer, effective immediately.
Experience and Role: Tina Katcheves brings over 20 years of experience in the biopharmaceutical industry, focusing on business development and corporate strategy, and will report to CEO Catherine Owen Adams.
Strategic Goals: Katcheves is expected to enhance Acadia's pipeline and growth opportunities, leveraging her extensive background from previous roles at Teva Pharmaceuticals and Bristol Myers Squibb.
Company Mission: Acadia Pharmaceuticals aims to advance treatments for neurological and rare diseases, having already developed FDA-approved drugs for conditions like Parkinson’s disease psychosis and Rett syndrome.
ACAD
$26.8+Infinity%1D
Analyst Views on ACAD
Wall Street analysts forecast ACAD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACAD is 30.24 USD with a low forecast of 21.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast ACAD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACAD is 30.24 USD with a low forecast of 21.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
5 Hold
0 Sell
Moderate Buy
Current: 27.260
Low
21.00
Averages
30.24
High
39.00
Current: 27.260
Low
21.00
Averages
30.24
High
39.00
H.C. Wainwright
Buy
maintain
$32 -> $37
2025-12-15
New
Reason
H.C. Wainwright
Price Target
$32 -> $37
2025-12-15
New
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Acadia Pharmaceuticals to $37 from $32 and keeps a Buy rating on the shares following the approval of Daybue Stix. The approval unlocks access for patients who previously couldn't swallow the large liquid volumes, the analyst tells investors in a research note. The firm's key opinion leader analysis suggests the powder formulation could reduce stomach issues by removing specific additives, while solving the taste struggles that cause families to stop treatment.
Stifel
Paul Matteis
Hold
maintain
$24 -> $25
2025-12-11
Reason
Stifel
Paul Matteis
Price Target
$24 -> $25
2025-12-11
maintain
Hold
Reason
Stifel analyst Paul Matteis raised the firm's price target on Acadia Pharmaceuticals to $25 from $24 and keeps a Hold rating on the shares. The firm "refreshed diligence" on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.
Mizuho
Neutral
maintain
$24 -> $29
2025-12-02
Reason
Mizuho
Price Target
$24 -> $29
2025-12-02
maintain
Neutral
Reason
Mizuho raised the firm's price target on Acadia Pharmaceuticals to $29 from $24 and keeps a Neutral rating on the shares. The firm upped the company's sales estimates post the "solid" Q4 report, driven by higher Nuplazid expectations. However, it sees a balanced risk/reward at current share levels.
JPMorgan
Tessa Romero
Overweight
downgrade
$33 -> $31
2025-11-17
Reason
JPMorgan
Tessa Romero
Price Target
$33 -> $31
2025-11-17
downgrade
Overweight
Reason
JPMorgan analyst Tessa Romero lowered the firm's price target on Acadia Pharmaceuticals to $31 from $33 and keeps an Overweight rating on the shares. The firm updated the company's model post earnings.
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
